ATB-429

ATB-429 is a small-molecule hydrogen sulfide (H2S)-releasing derivative of mesalamine, created by covalently linking mesalamine to the H2S-donor 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione (ADT-OH) to enhance anti-inflammatory efficacy in the gastrointestinal tract.[1][3] In preclinical models of colitis, ATB-429 demonstrated markedly greater anti-inflammatory potency than mesalamine, reducing disease activity, granulocyte infiltration, pro-inflammatory cytokines (including TNFα, IFNγ, IL-2, IL-6, RANTES, iNOS), and visceral pain, while sparing IL-10 expression and suppressing NF-κB activation in monocytes.[1][5][9] ATB-429 also protects against experimental colitis and necrotizing enterocolitis by stabilizing mucus and microbiota biofilms, increasing mesenteric blood flow, and exerting direct effects on gut microbiota, including chelation of luminal iron and modulation of purine/pyrimidine metabolism that reduce bacterial virulence without majorly altering community composition.[3][4][7] The compound has been developed and characterized by Antibe Therapeutics and academic collaborators as a potential therapy for inflammatory bowel disease and other inflammatory intestinal conditions, but remains at the experimental, non-approved stage.[3][4]

Other names

Benzoic acid, 5-amino-2-hydroxy-, 4-(3-thioxo-3H-1,2-dithiol-4-yl)phenyl ester5-amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-(1,2)dithiol-3yl)phenyl ester